Results 31 to 40 of about 17,959 (132)
Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal–CA1 projection
BMC Neuroscience, 2021 Background Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate receptor antagonist, has been shown to improve cognitive functions in animal models of Alzheimer’s disease (AD).
Peng Li +5 more
doaj +1 more source
Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. [PDF]
PLoS ONE, 2012 BackgroundAgitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and ...
Chris Fox +9 more
doaj +1 more source
Frontiers in Oncology, 2023 IntroductionCranial irradiation (IR) negatively regulates hippocampal neurogenesis and causes cognitive dysfunctions in cancer survivors, especially in pediatric patients. IR decreases proliferation of neural stem/progenitor cells (NSPC) and consequently
Georgios Alkis Zisiadis +6 more
doaj +1 more source
Molecular Pain, 2019 Background Memantine is one of the important clinical medications in treating moderate to severe Alzheimer disease. The effect of memantine on preventing or treating punctate allodynia has been thoroughly studied but not on the induction of dynamic ...
Yangyang Chen +5 more
doaj +1 more source
Modulatory Effects of Memantine on Neuronal Response Properties in Rat Barrel Cortex
Basic and Clinical Neuroscience, 2021 Introduction: Memantine as N-Methyl-D-Aspartic Acid (NMDA) receptor antagonist is used in some neurological disorders. Moreover, memantine presents modulatory effects on the somatosensory information processing in healthy subjects.
Mahin Nasiri +7 more
doaj
Memantine inhibits α3β2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteries. [PDF]
PLoS ONE, 2012 Memantine, an NMDA receptor antagonist used for treatment of Alzheimer's disease (AD), is known to block the nicotinic acetylcholine receptors (nAChRs) in the central nervous system (CNS).
Reggie Hui-Chao Lee +6 more
doaj +1 more source
Possible Antidepressant Effects of Memantine—Systematic Review with a Case Study
Pharmaceuticals, 2021 The treatment of bipolar depression is hampered by the inadequate efficacy of antidepressants, moderate effect of mood stabilizers, and the side effects of some second-generation antipsychotics.
Marek Krzystanek +4 more
doaj +1 more source
Autism Research, EarlyView.ABSTRACT Irritability is a prevalent and impairing feature associated with autism, yet remains poorly understood, particularly in adults. Drawing heavily on insights translated from pediatric and transdiagnostic literatures, we propose that irritability in autistic individuals often reflects a psychophysiological stress or threat response, rooted in a ...
Hsiang‐Yuan Lin +3 more
wiley +1 more source
Frontiers in Pharmacology, 2019 Alpha7 nicotinic acetylcholine receptors (nAChRs) play an important role in learning and memory and are promising targets for pharmacological cognitive enhancement.
Zsolt Kristóf Bali +15 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This study aimed to investigate a set of pharmacodynamic biomarkers reflecting acute, delayed and sustained central nervous system effects of S‐ketamine, used as a tool compound for rapid‐acting antidepressant activity, with the goal of informing biomarker strategies for delayed antidepressant effects.
Catherine M. K. E. de Cuba +11 more
wiley +1 more source